A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Clinical trial NCT06033261 · COMPLETED
Trial details
- NCT number
- NCT06033261
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-06
- Primary completion
- 2025-04-25
- Enrollment
- 303
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.